ANTIBODIES AGAINST THE MUC18 ANTIGEN

(19)

(11)

EP 1 470 146 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	12.09.2007 Bulletin 2007/37

(45)	Mention of the grant of the patent:
	13.06.2007 Bulletin 2007/24

(21)	Application number: 02797516.8

(22)	Date of filing: 26.12.2002

(51)

International Patent Classification (IPC):

C07H 21/04^(2006.01)
A61K 39/395^(2006.01)
A61K 47/48^(2006.01)

C07K 16/00^(2006.01)
C07K 16/28^(2006.01)

(86)	International application number:
	PCT/US2002/041581

(87)	International publication number:
	WO 2003/057838 (17.07.2003 Gazette 2003/29)

(54)	ANTIBODIES AGAINST THE MUC18 ANTIGEN ANTIKÖRPER GEGEN DAS MUC18-ANTIGEN ANTICORPS CONTRE L'ANTIGENE MUC18

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR

(30)

Priority:

28.12.2001 US 346299 P

(43)	Date of publication of application:
	27.10.2004 Bulletin 2004/44

(73)	Proprietor: Amgen Fremont Inc.
	Fremont, CA 94555 (US)

(72)	Inventors:
	GREEN, Larry L. San Francisco, CA 94114 (US) BAR-ELI, Menashe Houston, Texas 77030 (US)

(74)	Representative: Brants, Johan P.E. et al
	De Clercq, Brants & Partners cv Edgard Gevaertdreef 10a 9830 Sint-Martens-Latem 9830 Sint-Martens-Latem (BE)

(56)

References cited: :

WO-A1-00/76310
WO-A2-03/057006

WO-A2-02/077172

XIE X ET AL: "Expression of MCAM/MUC18 by human melanoma cells leads to increasesd tumor growht and metastasis" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 57, 1 June 1997 (1997-06-01), pages 2295-2303, XP002955245 ISSN: 0008-5472
PICKL W F ET AL: "MUC18/MCAM (CD146), an activation antigen of human T lymphocytes." JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 MAR 1997, vol. 158, no. 5, 1 March 1997 (1997-03-01), pages 2107-2115, XP002314616 ISSN: 0022-1767
WIMAZAL F ET AL: "Expression of homing receptors and related molecules on human mast cells and basophils: A comparative analysis using multi-color flow cytometry and toluidine blue/immunofluorescence staining techniques" TISSUE ANTIGENS, vol. 54, no. 5, November 1999 (1999-11), pages 499-507, XP002314617 ISSN: 0001-2815
MILLS L ET AL: "Fully human antibodies to MCAM/MUC 18 inhibit tumor growth and metastasis of human melanoma" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 62, 1 September 2002 (2002-09-01), pages 5106-5114, XP002965328 ISSN: 0008-5472
SIVAM G ET AL: "Immunotoxins to a human melanoma-associated antigen: Comparison of gelonin with ricin and other A chain conjugates" CANCER RESEARCH 1987 UNITED STATES, vol. 47, no. 12, 1987, pages 3169-3173, XP009042900
HIGUCHI T. ET AL.: 'Cyclic AMP enhances the expression of an extravillous trophoblast marker, melanoma cell adhesion molecule, in choriocarcinoma cell JEG3 and human chorionic villous explant cultures' MOLUCULAR HUMAN PRODUCTION vol. 9, no. 5-6, May 2003, pages 359 - 366, XP008052369
SHIH L.M. ET AL.: 'The cell-cell adhesion receptor Mel-CAM acts as a tumor suppressor in breast carcinoma' vol. 151, no. 3, September 1997, pages 745 - 751, XP008009110

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).